Skip to Content

Sofosbuvir / Velpatasvir Dosage

Applies to the following strength(s): 400 mg-100 mg

The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.

Usual Adult Dose for:

Additional dosage information:

Usual Adult Dose for Chronic Hepatitis C

1 tablet orally once a day

Regimen and Duration of Therapy:
-Patients without cirrhosis and patients with compensated cirrhosis (Child-Pugh A): Sofosbuvir-velpatasvir for 12 weeks
-Patients with decompensated cirrhosis (Child-Pugh B or C): Sofosbuvir-velpatasvir and ribavirin for 12 weeks

Comments:
-If applicable, the manufacturer product information for ribavirin should be consulted regarding dosing (including dose adjustments).

Uses: For the treatment of chronic HCV genotype 1, 2, 3, 4, 5, or 6 infection
-In patients without cirrhosis or with compensated cirrhosis
-In combination with ribavirin: In patients with decompensated cirrhosis

Renal Dose Adjustments

Mild or moderate renal dysfunction: No adjustment recommended.
Severe renal dysfunction (estimated glomerular filtration rate less than 30 mL/min/1.73 m2): Data not available

Comments:
-Safety and efficacy not established in patients with severe renal dysfunction; dose not established due to higher exposures of the main sofosbuvir metabolite.

Liver Dose Adjustments

Mild, moderate, or severe liver dysfunction (Child-Pugh A, B, or C): No adjustment recommended.

Precautions

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

ESRD requiring hemodialysis: Data not available

Comments:
-Safety and efficacy not established in ESRD patients requiring hemodialysis; dose not established due to higher exposures of the main sofosbuvir metabolite.

Other Comments

Administration advice:
-May take without regard to food
-Consult the manufacturer product information regarding missed doses.

Storage requirements:
-Store below 30C (86F) in the original container

General:
-If applicable, the manufacturer product information for ribavirin should be consulted for additional information.

Monitoring:
-General: Clinical monitoring in decompensated cirrhosis patients (as clinically indicated)
-Hepatic: Hepatic laboratory values, including direct bilirubin, in decompensated cirrhosis patients (as clinically indicated)

Patient advice:
-Read the US FDA-approved patient labeling (Patient Information).
-Seek medical evaluation at once if signs/symptoms of bradycardia (e.g., near-fainting/fainting, dizziness/lightheadedness, malaise, weakness, excessive tiredness, shortness of breath, chest pain, confusion/memory problems) develop.

Hide